Abstract | OBJECTIVES: MATERIALS AND METHODS: This is a single-center, non-randomized prospective phase II study. Patients with unresectable stage III NSCLC were treated with paclitaxel 15 mg/m(2) IV, followed by TTR 6 h later on Monday/Wednesday/Friday, and TTR only on Tuesday/Thursday mornings (total 55 Gy). Full dose adjuvant chemotherapy consisted of intravenous carboplatin (AUC 5) on day 1, gemcitabine 1000 mg/m(2) on days 1 and 8, every 21 days for 4 cycles. The primary endpoint was overall survival (OS). Secondary endpoints were overall response rate (ORR), and toxicities. RESULTS: CONCLUSION:
|
Authors | Jun Zhang, Hiram A Gay, Suzanne Russo, Teresa Parent, Raid Aljumaily, Paul R Walker |
Journal | Lung cancer (Amsterdam, Netherlands)
(Lung Cancer)
Vol. 83
Issue 1
Pg. 67-72
(Jan 2014)
ISSN: 1872-8332 [Electronic] Ireland |
PMID | 24246506
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Copyright | Copyright © 2013 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Deoxycytidine
- Carboplatin
- Paclitaxel
- Gemcitabine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carboplatin
(administration & dosage, adverse effects)
- Carcinoma, Non-Small-Cell Lung
(therapy)
- Chemotherapy, Adjuvant
- Combined Modality Therapy
- Deoxycytidine
(administration & dosage, adverse effects, analogs & derivatives)
- Female
- Humans
- Lung Neoplasms
(therapy)
- Male
- Middle Aged
- Neoplasm Staging
- Paclitaxel
(administration & dosage, adverse effects)
- Radiotherapy
- Thorax
(pathology, radiation effects)
- Gemcitabine
|